Industry Report
This report summarizes the challenges and policy recommendations to realize the vision of the pharmaceutical industry.
Current Situation and Challenges Surrounding the Pharmaceutical Industry - To Deliver Better Medicines to the World
Part I. Innovation and New Drug Creation
(December 2014)
Several paradigm shifts are currently taking place in the global pharmaceutical industry, which faces numerous challenges. In this project, the report is divided into three parts to provide an overview of the future of the pharmaceutical industry in Japan: (1) Sustainability of innovative drug discovery, (2) Patient-centered medicine and drug development, and (3) The pharmaceutical industry in the context of global change.
The first part focused on pharmaceutical R&D, analyzing the current state of innovation and new drug creation. First, as a transition of innovation in pharmaceutical R&D, the report highlighted recent trends in biopharmaceuticals, personalized medicine, regenerative medicine, and preventive/preemptive medicine, which have been the focus of much attention in recent years. Next, as challenges we are facing, we analyzed the response to unmet medical needs, pharmaceutical R&D productivity, and international competitiveness of R&D. Finally, the current status of personalized medicine, drug repositioning, open innovation, and outsourcing were summarized as directions for R&D to address these issues.
Part II: Changes in the Environment Surrounding Patients
(December 2014)
In the second part of the report, the author placed patients at the center and discussed "health literacy," which refers to the flow of information gathering and understanding by patients themselves, in order to "change patients' awareness" of medical care. He also discussed "patient-focused new drug development," which requires not only the physician's viewpoint but also the patient's viewpoint in new drug development, and incorporates the sensibilities of patients, which do not necessarily coincide with those of physicians, in the development of new drugs. Furthermore, "Patient Participatory Medicine and HTA" was discussed from the aspect of value judgment of pharmaceuticals focusing on the patient's viewpoint, and the risks that patients encounter in relation to pharmaceuticals were discussed as "Risks Surrounding Patients".
Part III Social Environment and Business Structure
(Apr 2015)
The third part of the report reviewed the variables of the phenomena that have surfaced today in terms of the social environment, the healthcare environment, and the pharmaceutical market. There are various issues that the pharmaceutical industry must address in the future, such as the aging of the population in developed countries, the expansion of markets in emerging countries as a result of economic development, and the response to global health in developing countries.
Future Vision of the Pharmaceutical Industry -Mission and Challenges for the Industry toward 2015
(May 2007)
This report looks ahead to the ideal state of the pharmaceutical industry in 2015, analyzes and examines from various perspectives the issues that need to be addressed and the direction of necessary reforms to realize this vision. Chapter 1 provides an overview of the changes in the environment surrounding the pharmaceutical industry. In Chapter 2, we look ahead to the year 2015, and discuss the future of the pharmaceutical industry. Chapter 3 analyzes the current status and challenges of the pharmaceutical industry from the perspectives of drug discovery infrastructure, R&D environment, pharmaceutical markets, and industrial competitiveness, and Chapter 4 presents the direction of reforms considered necessary.
| Chapter 1 | Environmental Changes Surrounding the Pharmaceutical Industry |
|---|---|
| Chapter 2 | The Future of the Pharmaceutical Industry in 2015 |
| Chapter 3 | Current Status and Challenges of the Pharmaceutical Industry |
| Chapter 4 | Toward 2015 |
The Current State of the Pharmaceutical Industry and Challenges Ahead - Toward Enhancing Competitiveness as a "Place for Drug Discovery
(November 2005)
Only a few countries in the world are capable of continuously creating new drugs. As one of the countries that creates new drugs, Japan has a role to play in responding to unmet medical needs in our country and contributing to global healthcare. Strengthening Japan's competitiveness as a "place for drug discovery" will not only contribute to the health of the Japanese people through the creation of innovative new drugs, but will also contribute to the development of life sciences through advanced research and development activities and to economic growth as a high value-added industry.
This report analyzes the current status and challenges of Japan's pharmaceutical industry through international comparisons, and makes recommendations for strengthening Japan's competitiveness as a "place for drug discovery" based on this analysis.
| Chapter 1 | Competitiveness Ranking of Japan as a "Place for Drug Discovery |
|---|---|
| Chapter 2 | Japan's Pharmaceutical Market |
| Chapter 3 | Japan's Pharmaceutical Price System |
| Chapter 4 | R&D Environment in Japan |
| Chapter 5 | Management Challenges for Japanese Pharmaceutical Companies |
| Chapter 6 | Recommendations for Improving Access to New Drugs |
Japan's Pharmaceutical Industry - Perspectives on International Competitiveness
(May 2001)
Only a few countries in the world are capable of continuously creating new drugs. As one of the countries that creates new drugs, Japan has a role to play in responding to unmet medical needs in our country and contributing to global healthcare. Strengthening Japan's competitiveness as a "place for drug discovery" will not only contribute to the health of the Japanese people through the creation of innovative new drugs, but will also contribute to the development of life sciences through advanced research and development activities and to economic growth as a high value-added industry.
This report analyzes the current status and challenges of the Japanese pharmaceutical industry through international comparisons, and makes recommendations for strengthening Japan's competitiveness as a "place for drug discovery.
-
As of December 2023This report was published and sold by the Iyaku Shuppan Center as a publication of the Pharmaceutical Manufacturers Association of Japan (PMAJ), but is now out of stock.
| Chapter 1 | Japan's Pharmaceutical Industry from the Perspective of International Competitiveness |
|---|---|
| Chapter 2 | High Dependence of Japanese Companies on the Domestic Market |
| Chapter 3 | Intense Market Competition under the NHI Drug Price Standard System |
| Chapter 4 | Disparity in Drug Discovery Technology |
| Chapter 5 | Background of the Technology Gap |
| Chapter 6 | The Pharmaceutical Industry's Lack of Consolidation |
Changes in the Competitive Environment Surrounding the Pharmaceutical Industry, M&A, and Globalization: An Analysis of the Results of an Attitude Survey
(March 2000)
A questionnaire survey of 83 member companies of the Japan Pharmaceutical Manufacturers Association (JPMA) was conducted to determine how R&D-oriented pharmaceutical companies perceive the merits of expanding their corporate scale and M&A as a method of expanding scale in the current competitive environment, as well as to clarify their current status and awareness of internationalization. The survey also clarified the current status and awareness of internationalization.
-
As of December 2023We are sorry to inform you that this report is no longer in stock.